PATHOLOGICA最新文献_第3页

Head and neck hematolymphoid proliferations: what is new? 头颈部淋巴细胞增生：有什么新发现？

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1207

Silvia Varricchio, Rosaria Cappiello, Francesca Magnoli, Daniela Russo, Giovanna Motta, Clara Bertuzzi, Elena Sabattini, Gennaro Ilardi, Mariarosaria Cervasio, Claudia Giordano, Alessandro Severino, Marco Picardi, Massimo Mascolo

{"title":"Head and neck hematolymphoid proliferations: what is new?","authors":"Silvia Varricchio, Rosaria Cappiello, Francesca Magnoli, Daniela Russo, Giovanna Motta, Clara Bertuzzi, Elena Sabattini, Gennaro Ilardi, Mariarosaria Cervasio, Claudia Giordano, Alessandro Severino, Marco Picardi, Massimo Mascolo","doi":"10.32074/1591-951X-1207","DOIUrl":"10.32074/1591-951X-1207","url":null,"abstract":"In 2024, the World Health Organization published its 5th edition of tumor classification, which comprises several updates and modifications in the \"blue book\" focused on head and neck tumors. These changes feature a systematized and expanded discussion on haematolymphoid proliferations using a multi-parameter approach that comprises clinical features, morphology, immunophenotype, and genetic data, with the latter becoming an essential characteristic for classification. Moreover, for the first time, the World Health Organization has included non-neoplastic diseases, such as reactive lymphoid proliferations, alongside several recognized independent disorders, including Epstein-Barr Virus positive mucocutaneous ulcers and IgG4-related diseases. Also, various neoplastic diseases, such as paediatric-type follicular lymphoma and large B-cell lymphoma with IRF4 rearrangement, are recognized as independent entities. Finally, the focus has expanded to include different types of histiocytic neoplasms. This review examines and illustrates the main changes and updates on hematolymphoid proliferation and neoplasia in the Head and Neck chapter of the 5th Edition of the Head and Neck WHO classification.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 2","pages":"101-110"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Head and neck synovial sarcoma in a woman with previous lymphoma and papillary thyroid carcinoma. 头颈部滑膜肉瘤1例既往有淋巴瘤和甲状腺乳头状癌。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1034

Mariano Lombardi, Daniela Lepanto, Eleonora Pisa, Valeria Midolo De Luca, Renato Lobrano, Simona Pessina, Chiara Zanetti, Marta Tagliabue, Elvio De Fiori, Fausto Maffini

引用次数: 0

One protocol to rule them all: a pilot study to identify the best fixation and decalcification approach for bone marrow biopsy immunohistochemistry. 一个方案来统治他们所有：一个试点研究，以确定最佳固定和脱钙方法骨髓活检免疫组织化学。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1065

Michele Paudice, Alessandro Gambella, Simona Pigozzi, Michela Campora, Francesca Pitto, Silvia Bozzano, Luca Mastracci, Federica Grillo

{"title":"One protocol to rule them all: a pilot study to identify the best fixation and decalcification approach for bone marrow biopsy immunohistochemistry.","authors":"Michele Paudice, Alessandro Gambella, Simona Pigozzi, Michela Campora, Francesca Pitto, Silvia Bozzano, Luca Mastracci, Federica Grillo","doi":"10.32074/1591-951X-1065","DOIUrl":"10.32074/1591-951X-1065","url":null,"abstract":"Objective: Standardization of the pre-analytical phases of bone marrow trephine biopsy (BM) has yet to be achieved. In particular, several fixative and decalcifying reagents with specific benefits and drawbacks are described, but only a few direct comparisons are available. This study aims to test the most used fixation and decalcification protocols and evaluate their effect on tissue antigenicity via immunohistochemistry (IHC).Methods: To avoid damaging and exhausting diagnostic BMs, we used \"surrogate\" BMs obtained from dedicated grossing of a non-pathologic spleen. Eleven fixation and decalcification protocols were tested, and their performances were evaluated via IHC protein expression of 25 biomarkers.Results: The IHC yield varied based on the fixative and decalcifying reagents, but the overall quality is mainly related to the fixative rather than the decalcifying phases. The protocol with the lowest number of inadequate IHC stains (5 out of 25) combined commercially available B5-based fixative and EDTA-based decalcifying reagents. The worst metrics (8 inadequate IHC stains out of 25) were obtained with a protocol based on \"in-house\" B5-based and EDTA-based reagents.Conclusions: We compared different protocols and found the best combination of fixative and decalcifying reagents for accurate IHC staining. These findings can improve bone marrow sample handling and standardization in pathology laboratories.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 2","pages":"145-152"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cholesterol granuloma. Another brick in the wall of mediastinal lesions. 胆固醇肉芽肿。纵隔病变壁上的另一块砖。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1054ER

Michela Campora, Giampiero Negri, Virgilio Longari, Maurilio Ponzoni

引用次数: 0

KRAS/NRAS variants and copy number alterations prognostically stratify patients with sinonasal melanoma. KRAS/NRAS变异和拷贝数改变对鼻窦黑色素瘤患者的预后分层有影响。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1088

Laura Libera, Nora Sahnane, Mario Turri-Zanoni, Fabiana Pettenon, Deborah Marchiori, Paolo Battaglia, Alberto Daniele Arosio, Daniela Furlan, Maurizio Bignami, Paolo Castelnuovo, Fausto Sessa, Carla Facco, Michele Cerati, Stefano La Rosa

{"title":"KRAS/NRAS variants and copy number alterations prognostically stratify patients with sinonasal melanoma.","authors":"Laura Libera, Nora Sahnane, Mario Turri-Zanoni, Fabiana Pettenon, Deborah Marchiori, Paolo Battaglia, Alberto Daniele Arosio, Daniela Furlan, Maurizio Bignami, Paolo Castelnuovo, Fausto Sessa, Carla Facco, Michele Cerati, Stefano La Rosa","doi":"10.32074/1591-951X-1088","DOIUrl":"10.32074/1591-951X-1088","url":null,"abstract":"Sino-nasal mucosal melanoma (SN-MM) is an aggressive and rare form of melanoma arising from mucosal melanocytes with pathogenesis unrelated to sun exposure. Conversely to cutaneous melanoma (CM), the molecular bases underling SN-MM development and progression are unclear, and no molecular predictive markers have been identified yet. To better define the molecular landscape of SN-MM, a retrospective series of 37 SN-MMs from 31 patients was analysed for both somatic mutations and cytogenetic alterations. The somatic mutation analysis identified the presence of a driver gene pathogenic variant in 54% of cases. In detail, mutually exclusive NRAS mutations were found in 42% of cases, KRAS mutations in 6%, and KIT mutations in 6% of cases. Remarkably, no BRAF mutations were detected. Patients with NRAS-mutated/KRAS-wild type (wt) melanomas showed better outcome than patients with NRAS-wt/KRAS-mutated melanomas, which were associated with multiple recurrences at local or regional sites. On the other hand, focusing on genomic alterations, copy number variants (loss of 1p36, loss of 3p/3q) were identified in 19% of SN-MMs, which showed poor overall survival and short disease-free survival with early metastatic dissemination. This work describes a new integrated characterization of both single nucleotide variants and, for the first time, genomic alteration in SN-MM, providing a new insight into molecular bases of these neoplasms and prompting further efforts for personalized clinical protocols according to tumour aggressiveness.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 2","pages":"121-130"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When to think of Sarcina sp. in histopathologic examination of gastrointestinal tract: insights from a one-year-old with esophagitis and gastric outlet obstruction. 在胃肠道的组织病理学检查中，什么时候应该想到Sarcina sp：来自1岁食管炎和胃出口梗阻的见解。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1114

Farzaneh Afshari, Maryam Khalesi, Nema Mohammadian Roshan, Amir Hossein Jafarian

引用次数: 0

Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists. 慢性肝病的活检：临床医生和病理学家共享路径的建议。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1063

Andrea Baiocchini, Maria Conti, Daniela Fanni, Francesca Romana Ponziani, Giuliano Alagna, Clara Balsano, Simone Carotti, Antonio Cossu, Guido Delle Monache, Shirin Demma, Maria Cristina Giustiniani, Vito Gomes, Cristina Manieli, Alessandra Moretti, Teresa Musarra, Valeria Pace Palitti, Giuseppe Perrone, Chiara Taffon, Francesca Terracciani, Umberto Vespasiani-Gentilucci, Teresa Zolfino, Giulia d'Amati

{"title":"Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists.","authors":"Andrea Baiocchini, Maria Conti, Daniela Fanni, Francesca Romana Ponziani, Giuliano Alagna, Clara Balsano, Simone Carotti, Antonio Cossu, Guido Delle Monache, Shirin Demma, Maria Cristina Giustiniani, Vito Gomes, Cristina Manieli, Alessandra Moretti, Teresa Musarra, Valeria Pace Palitti, Giuseppe Perrone, Chiara Taffon, Francesca Terracciani, Umberto Vespasiani-Gentilucci, Teresa Zolfino, Giulia d'Amati","doi":"10.32074/1591-951X-1063","DOIUrl":"10.32074/1591-951X-1063","url":null,"abstract":"Introduction: Liver biopsy is fundamental for characterizing chronic liver disease. Effective communication between specialists during the diagnostic process is crucial. This project aims to outline a diagnostic path shared by clinicians and pathologists, and to propose practical solutions at different stages of the diagnostic work-up, from clinical suspicion to the histology report in patients with chronic liver diseases.Methods: A panel of experts, within the methodological framework of lean management, joined two rounds of discussion sharing their professional experiences. They reached an agreement on the essential phases and actions of the diagnostic process, and built a shared diagnostic workflow.Results: The panel agreed on the importance of a standardized form to be filled with all relevant clinical and laboratory data to ensure the flow of information between the clinician and the pathologist. Further decisions were reached on the following practical issues: the advantage of performing liver biopsies in dedicated centers, the need for homogeneous procedures, and the minimum quality standards in all phases, including reporting. Finally, the panel agreed on the usefulness of digital pathology to exchange observations and opinions and to create a territorial network to discuss challenging cases.Conclusion: Sharing a diagnostic path between the pathologist and the clinician can be a powerful tool to improve both the timing and accuracy of the histology report.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 2","pages":"136-144"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma: PD-L1 and beyond. 复发/转移性头颈部鳞状细胞癌的免疫治疗：PD-L1及以上。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1092

Andrea Ascione, Andrea Botticelli, Martina Leopizzi, Edoardo Cerbelli, Alessio Cirillo, Diana Bellavia, Carlo Della Rocca, Giulia d'Amati, Bruna Cerbelli

{"title":"Immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma: PD-L1 and beyond.","authors":"Andrea Ascione, Andrea Botticelli, Martina Leopizzi, Edoardo Cerbelli, Alessio Cirillo, Diana Bellavia, Carlo Della Rocca, Giulia d'Amati, Bruna Cerbelli","doi":"10.32074/1591-951X-1092","DOIUrl":"10.32074/1591-951X-1092","url":null,"abstract":"Head and neck squamous cell carcinoma (HNSCC) is a prominent global health concern because of its high incidence, aggressive clinical behavior, and scarce therapeutic options. The management of these neoplasms in the recurrent/metastatic setting has been revolutionized following the results of key clinical trials, leading to the advent of immunotherapeutic agents targeting the PD-1/PD-L1 axis. Despite the exciting results obtained with the new drugs, immunotherapy is helpful only in a sizable minority of patients, and there is a pressing need to identify reliable predictive biomarkers for patient selection. The immunohistochemical assessment of PD-L1 expression was initially identified as a powerful and easily accessible predictive tool, and gained its place as the current standard for patient selection, but it has clear limitations. The imperfect predictive power of PD-L1 has resulted in a strong effort to discover additional clinical, pathological and molecular biomarkers such as tumor HPV status, mutational burden, microsatellite instability, and much more. In addition, the tumor microenvironment has been extensively studied searching for promising new biomarkers as potential avenues for refining patient selection and improvement of treatment outcomes. As we gain deeper understanding of the complex interplay between tumor biology, immune system, and tumor microenvironment, we are rapidly realizing that the perfect biomarker, the magic bullet, probably doesn't exist. On the other hand, with the introduction of new drugs on the horizon, integration of multiple variables in the context of combined predictive scores is shaping up to be our best weapon in this strife to treat each patient with the best possible drug.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 2","pages":"73-83"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Malpractice in head and neck cancer: a comprehensive medico-legal review. 头颈癌的医疗事故：全面的医学法律审查。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1001

Emanuele Capasso, Claudia Casella, Mariagrazia Marisei, Marco Macculi, Ilenia Bianchi, Pierpaolo Di Lorenzo

{"title":"Malpractice in head and neck cancer: a comprehensive medico-legal review.","authors":"Emanuele Capasso, Claudia Casella, Mariagrazia Marisei, Marco Macculi, Ilenia Bianchi, Pierpaolo Di Lorenzo","doi":"10.32074/1591-951X-1001","DOIUrl":"10.32074/1591-951X-1001","url":null,"abstract":"Head and neck (H&N) malignancies include a broad spectrum of clinical presentations and outcomes. Sources of risks, errors and mistakes are intrinsic to every therapeutical-diagnostic step leading to potential burden of malpractice allegations and threaten delivery of healthcare. The purpose of this review is to report key factors of malpractice litigation H&N neoplasms, analyzing its ethical-deontological and medico-legal aspects with a focus on Italian law. PubMed and Scopus databases were accessed to assess existing cases of oncological H&N malpractice. Twelve articles were identified according to search criteria in the selected period (2000-2024). Inclusion criteria lead to 6 articles pertaining to analysis of allegations of malpractice in H&N tumors. Diagnostic delay and informed consent issues are the most represented allegations. Poor access and lack of standardization in legal databases is commonly seen as a factor that holds back a thorough litigation analysis. This review adds evidence about common features of medical malpractice allegations through a medico-legal perspective that may help in adopting preventive strategies to mitigate risks and enhance patient safety. Combining data deriving from different studies, the paper contributes to understand the evolution of the trajectory of malpractice in this field.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 2","pages":"67-72"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of papillary thryoid carcinoma and its variants: multifocality in thyroid lobectomy and completion thyroidectomy - a single tertiary center retrospective study. 评估乳头状甲状腺癌及其变异：甲状腺小叶切除术和完全甲状腺切除术的多灶性-一项单三级中心回顾性研究。

IF 4.4

PATHOLOGICA Pub Date : 2025-04-01 DOI: 10.32074/1591-951X-1091

Carmine Bruno, Pietro Tralongo, Federica Vegni, Angela Feraco, Qianqian Zhang, Belen Padial-Urtueta, Angela Carlino, Alfredo Pontecorvi, Guido Fadda, Marco Raffaelli, Luigi Maria Larocca, Liron Pantanowitz, Esther Diana Rossi

{"title":"Evaluation of papillary thryoid carcinoma and its variants: multifocality in thyroid lobectomy and completion thyroidectomy - a single tertiary center retrospective study.","authors":"Carmine Bruno, Pietro Tralongo, Federica Vegni, Angela Feraco, Qianqian Zhang, Belen Padial-Urtueta, Angela Carlino, Alfredo Pontecorvi, Guido Fadda, Marco Raffaelli, Luigi Maria Larocca, Liron Pantanowitz, Esther Diana Rossi","doi":"10.32074/1591-951X-1091","DOIUrl":"10.32074/1591-951X-1091","url":null,"abstract":"Aims: The American Thyroid Association (ATA) updated guidelines for the treatment of thyroid cancer, leading to a less aggressive approach depending on clinical-pathological features. As a result, the possibility to perform lobectomy versus total thyroidectomy has significantly increased. The majority of thyroid cancers are indolent with an excellent prognosis, while only 15% of patients with well-differentiated carcinoma, including papillary thyroid carcinoma (PTC), have locally advanced thyroid cancer (LATC) at diagnosis. We reviewed our practice in treating thyroid carcinoma over the last decade.Methods: From January 2010 to December 2020, 1057 patients with uninodular benign and malignant thyroid lesions were reviewed.Results: Among these cases, 77% were women with a median age of 49.3 years. The series involved 307 malignant diagnoses (29.05%) including 196 (61.6%) classic PTC and 38 (12%) aggressive variants of PTC, mostly tall cell variant (30 cases, 9.4%). Among malignant cases, multifocality was microscopically documented in 84 cases (26.4%). Using the ATA distribution of risk, there were 239 cases in the low risk and 68 in the intermediate risk categories. Second surgery was assessed in a total of 150 cases, showing 42 cases with additional thyroid cancer foci in the other lobe (26 single vs 16 multiple foci). Ten cases had metastatic perithyroidal lymph nodes.Conclusion: Our data could be the basis for performing a longitudinal study in order to establish which risk factors can predict bilateral involvement and to suggest a tailored surgical approach.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 2","pages":"111-120"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0